It was a very interesting year, especially since FDA finally released some long-awaited social media guidance for the pharma industry. 2014 was also notable for the proliferation of pharma mobile health apps, which is another emerging area that needs FDA guidance. FDA has said that the guidances it has issued so far do not include mobile. Finally, it was the year of high prices - for both branded and generic drugs.
See below for notes.